vs
ALLIENT INC（ALNT）与Apellis Pharmaceuticals, Inc.（APLS）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是ALLIENT INC的1.4倍（$199.9M vs $143.4M），ALLIENT INC净利率更高（4.5% vs -29.5%，领先33.9%），ALLIENT INC同比增速更快（17.5% vs -5.9%），ALLIENT INC自由现金流更多（$11.7M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.2%）
Allient Inc是一家全球化技术制造企业，主营精密运动、控制及电源解决方案的设计、生产与分销，核心服务航空航天、国防、医疗设备、工业自动化、商用出行等领域，业务覆盖北美、欧洲及亚太地区。
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
ALNT vs APLS — 直观对比
营收规模更大
APLS
是对方的1.4倍
$143.4M
营收增速更快
ALNT
高出23.4%
-5.9%
净利率更高
ALNT
高出33.9%
-29.5%
自由现金流更多
ALNT
多$25.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $143.4M | $199.9M |
| 净利润 | $6.4M | $-59.0M |
| 毛利率 | 32.4% | — |
| 营业利润率 | 7.9% | -25.6% |
| 净利率 | 4.5% | -29.5% |
| 营收同比 | 17.5% | -5.9% |
| 净利润同比 | 111.8% | -62.2% |
| 每股收益（稀释后） | $0.38 | $-0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALNTAPLS
| Q4 25 | $143.4M | $199.9M | ||
| Q3 25 | $138.7M | $458.6M | ||
| Q2 25 | $139.6M | $178.5M | ||
| Q1 25 | $132.8M | $166.8M | ||
| Q4 24 | $122.0M | $212.5M | ||
| Q3 24 | $125.2M | $196.8M | ||
| Q2 24 | $136.0M | $199.7M | ||
| Q1 24 | $146.7M | $172.3M |
净利润ALNTAPLS
| Q4 25 | $6.4M | $-59.0M | ||
| Q3 25 | $6.5M | $215.7M | ||
| Q2 25 | $5.6M | $-42.2M | ||
| Q1 25 | $3.6M | $-92.2M | ||
| Q4 24 | $3.0M | $-36.4M | ||
| Q3 24 | $2.1M | $-57.4M | ||
| Q2 24 | $1.1M | $-37.7M | ||
| Q1 24 | $6.9M | $-66.4M |
毛利率ALNTAPLS
| Q4 25 | 32.4% | — | ||
| Q3 25 | 33.3% | — | ||
| Q2 25 | 33.2% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 31.4% | — | ||
| Q2 24 | 29.9% | — | ||
| Q1 24 | 32.3% | — |
营业利润率ALNTAPLS
| Q4 25 | 7.9% | -25.6% | ||
| Q3 25 | 8.8% | 48.7% | ||
| Q2 25 | 8.4% | -18.6% | ||
| Q1 25 | 6.6% | -50.0% | ||
| Q4 24 | 5.3% | -12.3% | ||
| Q3 24 | 5.3% | -24.0% | ||
| Q2 24 | 3.6% | -14.7% | ||
| Q1 24 | 8.2% | -36.0% |
净利率ALNTAPLS
| Q4 25 | 4.5% | -29.5% | ||
| Q3 25 | 4.7% | 47.0% | ||
| Q2 25 | 4.0% | -23.6% | ||
| Q1 25 | 2.7% | -55.3% | ||
| Q4 24 | 2.5% | -17.1% | ||
| Q3 24 | 1.7% | -29.2% | ||
| Q2 24 | 0.8% | -18.9% | ||
| Q1 24 | 4.7% | -38.5% |
每股收益（稀释后）ALNTAPLS
| Q4 25 | $0.38 | $-0.40 | ||
| Q3 25 | $0.39 | $1.67 | ||
| Q2 25 | $0.34 | $-0.33 | ||
| Q1 25 | $0.21 | $-0.74 | ||
| Q4 24 | $0.17 | $-0.30 | ||
| Q3 24 | $0.13 | $-0.46 | ||
| Q2 24 | $0.07 | $-0.30 | ||
| Q1 24 | $0.42 | $-0.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $40.7M | $466.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $301.5M | $370.1M |
| 总资产 | $577.6M | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ALNTAPLS
| Q4 25 | $40.7M | $466.2M | ||
| Q3 25 | $39.5M | $479.2M | ||
| Q2 25 | $49.9M | $370.0M | ||
| Q1 25 | $47.8M | $358.4M | ||
| Q4 24 | $36.1M | $411.3M | ||
| Q3 24 | $37.1M | $396.9M | ||
| Q2 24 | $31.3M | $360.1M | ||
| Q1 24 | $31.5M | $325.9M |
总债务ALNTAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $93.1M |
股东权益ALNTAPLS
| Q4 25 | $301.5M | $370.1M | ||
| Q3 25 | $294.2M | $401.2M | ||
| Q2 25 | $289.1M | $156.3M | ||
| Q1 25 | $272.8M | $164.2M | ||
| Q4 24 | $264.9M | $228.5M | ||
| Q3 24 | $272.9M | $237.1M | ||
| Q2 24 | $265.7M | $264.3M | ||
| Q1 24 | $267.1M | $266.7M |
总资产ALNTAPLS
| Q4 25 | $577.6M | $1.1B | ||
| Q3 25 | $585.1M | $1.1B | ||
| Q2 25 | $588.1M | $821.4M | ||
| Q1 25 | $586.9M | $807.3M | ||
| Q4 24 | $575.8M | $885.1M | ||
| Q3 24 | $596.4M | $901.9M | ||
| Q2 24 | $595.8M | $904.5M | ||
| Q1 24 | $611.6M | $831.9M |
负债/权益比ALNTAPLS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.35× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.6M | $-14.2M |
| 自由现金流经营现金流 - 资本支出 | $11.7M | $-14.3M |
| 自由现金流率自由现金流/营收 | 8.1% | -7.1% |
| 资本支出强度资本支出/营收 | 1.3% | 0.1% |
| 现金转化率经营现金流/净利润 | 2.12× | — |
| 过去12个月自由现金流最近4个季度 | $49.7M | $45.0M |
8季度趋势，按日历期对齐
经营现金流ALNTAPLS
| Q4 25 | $13.6M | $-14.2M | ||
| Q3 25 | $4.7M | $108.5M | ||
| Q2 25 | $24.5M | $4.4M | ||
| Q1 25 | $13.9M | $-53.4M | ||
| Q4 24 | $12.4M | $19.4M | ||
| Q3 24 | $12.1M | $34.1M | ||
| Q2 24 | $8.2M | $-8.3M | ||
| Q1 24 | $9.2M | $-133.0M |
自由现金流ALNTAPLS
| Q4 25 | $11.7M | $-14.3M | ||
| Q3 25 | $2.8M | $108.3M | ||
| Q2 25 | $22.4M | $4.4M | ||
| Q1 25 | $12.9M | $-53.4M | ||
| Q4 24 | $9.6M | $19.3M | ||
| Q3 24 | $10.5M | — | ||
| Q2 24 | $5.8M | $-8.4M | ||
| Q1 24 | $6.2M | $-133.3M |
自由现金流率ALNTAPLS
| Q4 25 | 8.1% | -7.1% | ||
| Q3 25 | 2.0% | 23.6% | ||
| Q2 25 | 16.0% | 2.5% | ||
| Q1 25 | 9.7% | -32.0% | ||
| Q4 24 | 7.9% | 9.1% | ||
| Q3 24 | 8.4% | — | ||
| Q2 24 | 4.3% | -4.2% | ||
| Q1 24 | 4.2% | -77.3% |
资本支出强度ALNTAPLS
| Q4 25 | 1.3% | 0.1% | ||
| Q3 25 | 1.4% | 0.0% | ||
| Q2 25 | 1.5% | 0.0% | ||
| Q1 25 | 0.8% | 0.0% | ||
| Q4 24 | 2.3% | 0.0% | ||
| Q3 24 | 1.3% | 0.0% | ||
| Q2 24 | 1.7% | 0.0% | ||
| Q1 24 | 2.0% | 0.2% |
现金转化率ALNTAPLS
| Q4 25 | 2.12× | — | ||
| Q3 25 | 0.72× | 0.50× | ||
| Q2 25 | 4.36× | — | ||
| Q1 25 | 3.92× | — | ||
| Q4 24 | 4.11× | — | ||
| Q3 24 | 5.75× | — | ||
| Q2 24 | 7.13× | — | ||
| Q1 24 | 1.33× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALNT
| Industrial And Electronics | $69.5M | 48% |
| Vehicle | $25.7M | 18% |
| Other | $20.9M | 15% |
| Aerospace And Defense | $20.6M | 14% |
| Distribution And Other Target Market | $6.7M | 5% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
